|
Hey Cheri!
I agree with DanL on this one.
I've done some looking, and I can't find much in terms of results for TPA, other than the Phase 1 study the doc you are working with did. Like most Phase 1 studies, that was about finding the correct dosing and figuring out how to deal with side effects. They evidently felt they got that figured out and terminated that study. The one you'd be enrolled in is aimed at finding out whether the drug can produce improvement in at least 20% of patients.
So, like Dan says, it would be nice to know about the results in China. It may be just the thing you need, but there's just not much US data to go on at the moment.
Estybon is definitely further along in the development and testing curve.
Take care!
Greg
__________________
Greg, 59, dx MDS RCMD Int-1 03/10, 8+ & Dup1(q21q31). NIH Campath 11/2010. Non-responder. Tiny telomeres. TERT mutation. Danazol at NIH 12/11. TX independent 7/12. Pancreatitis 4/15. 15% blasts 4/16. DX RAEB-2. Beginning Vidaza to prep for MUD STC. Check out my blog at www.greghankins.com
|